

**Table S3. Intracranial tumor response by prior CNS radiotherapy as assessed by independent review committee.** Tumor response of patients with *RET* fusion-positive NSCLC and non-measurable intracranial disease is shown by prior CNS radiotherapy status.

	Patients with <i>RET</i> fusion-positive NSCLC and non-measurable CNS disease		
	All patients (N=58)	Patients without prior CNS radiotherapy (N=21)	Patients with prior CNS radiotherapy (N=37) <sup>a</sup>
Intracranial objective response rate, n (%)	20 (34)	11 (52)	9 (24)
95% confidence interval <sup>b</sup>	23–48	30–74	12–41
Intracranial best overall response, n (%)			
Complete response	20 (34)	11 (52)	9 (24)
Non-CR/Non-PD	29 (50)	6 (29)	23 (62)
Progressive disease	5 (9)	1 (5)	4 (11)
Non evaluable	2 (3)	2 (10)	0
Undefined <sup>c</sup>	2 (3)	1 (5)	1 (3)

Abbreviations: CNS, central nervous system; CR, complete response; PD, progressive disease

<sup>a</sup> Of the 37 patients who received prior radiotherapy, 27 completed radiotherapy >2 months prior to treatment.

<sup>b</sup> 95% confidence interval was calculated using Clopper-Pearson method.

<sup>c</sup> Patients were assessed by investigator as having non-target brain lesion at baseline, but no disease was identified by IRC.

Note: CR and non-CR/non-PD corresponds to the clinical benefit rate for non-measurable intracranial disease.